Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International Journal of Rheumatic Diseases

• Publication date

  2017-03-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/1756-185X.13068PMID 28332780
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The global burden

  2018cited by this paper
• A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes

  2016cited by this paper
• Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study.

  2016cited by this paper
• Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys.

  2016cited by this paper
• Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis

  2015cited by this paper
• Commentary on recent therapeutic guidelines for osteoarthritis.

  2015cited by this paper
• OARSI guidelines for the non-surgical management of knee osteoarthritis.

  2014cited by this paper
• An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

  2014cited by this paper
• Risk of Bias and Brand Explain the Observed Inconsistency in Trials on Glucosamine for Symptomatic Relief of Osteoarthritis: A Meta‐Analysis of Placebo‐Controlled Trials

  2014cited by this paper
• The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study

  2014cited by this paper
• Risk of bias and brand explain the observed inconsistency in trials on glucosamine for osteoarthritis:a meta-analysis of placebo-controlled trials

  2014cited by this paper
• Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition.

  2013cited by this paper
• How to define responders in osteoarthritis

  2013cited by this paper
• Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties

  2012cited by this paper
• Long‐term oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up‐regulation of MMP‐3 mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs

  2012cited by this paper
• Role of glucosamine in the treatment for osteoarthritis

  2012cited by this paper
• American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee

  2012cited by this paper
• The need to address the burden of musculoskeletal conditions.

  2012cited by this paper
• Experimental Pharmacology of Glucosamine Sulfate

  2011cited by this paper
• The epidemiology of osteoarthritis in Asia

  2011cited by this paper
• The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.

  2010cited by this paper
• Glucosamine sulphate in the treatment of knee osteoarthritis: cost‐effectiveness comparison with paracetamol

  2010cited by this paper
• OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009.

  2010cited by this paper
• Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations

  2009cited by this paper
• The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation.

  2009cited by this paper
• A study on indirect and intangible costs for patients with knee osteoarthritis in Singapore.

  2008cited by this paper
• Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials.

  2008cited by this paper
• Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose.

  2007cited by this paper
• The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest.

  2007cited by this paper
• Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator.

  2007cited by this paper
• Short‐term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta‐analysis of randomised placebo‐controlled trials

  2007cited by this paper
• Direct and indirect costs of osteoarthritis in Singapore: a comparative study among multiethnic Asian patients with osteoarthritis.

  2007cited by this paper
• Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants.

  2006cited by this paper
• Factors predisposing women to chronic pelvic pain: systematic review

  2006cited by this paper
• Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants.

  2005cited by this paper
• Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis.

  2005cited by this paper
• Glucosamine therapy for treating osteoarthritis.

  2005cited by this paper
• Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man.

  2005cited by this paper
• EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

  2003cited by this paper
• Relief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials.

  2003cited by this paper
• Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes.

  2003cited by this paper
• Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes

  2003cited by this paper
• Glucosamine modulates IL‐1‐induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF‐κB pathway

  2002cited by this paper
• Active ingredient consistency of commercially available glucosamine sulfate products.

  2002cited by this paper
• Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study.

  2002cited by this paper
• Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial.

  2001cited by this paper
• Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis.

  2000cited by this paper
• Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee.

  1999cited by this paper
• Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events.

  1999cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• The biology of osteoarthritis.

  1989cited by this paper

• Azido acetylated-glucosamine Schiff base copper complexes accumulate in cancer cells and induce apoptosis in vitro:High selective cytotoxicity against HepG-2 cells

  2025cites this paper
• Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges.

  2025cites this paper
• Pharmacist-Driven Chondroprotection in Osteoarthritis: A Multifaceted Approach Using Patient Education, Information Visualization, and Lifestyle Integration

  2025cites this paper
• Comparison of functional performance outcomes between oral patented crystalline glucosamine sulfate and platelet-rich plasma among knee osteoarthritis patients: a propensity score matching analysis

  2024cites this paper
• Health Technology Assessment of Different Glucosamine Formulations and Preparations Currently Marketed in Thailand

  2023cites this paper
• Symptomatic slow-acting drugs (SYSADOAs)/disease modifying anti-osteoarthrosis drugs (DMOADs) in the treatment of osteoarthrosis: what is the opinion of the different rheumatology/osteoarthritis societies in 2021?

  2022cites this paper
• Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations

  2022cites this paper
• 2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint

  2021cites this paper
• Chondroprotectives used for the treatment of knee osteoarthritis: A comment

  2021cites this paper
• A Malaysian Delphi consensus on managing knee osteoarthritis

  2021cites this paper
• 2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint

  2021cites this paper
• Pharmacologic Agents for Knee Articular Cartilage Injury and Disease

  2020cites this paper
• Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon

  2020cites this paper
• [Symptomatic slow-acting drugs in the treatment of osteoarthritis: focus on glucosamine preparations].

  2020cites this paper
• Appropriateness of clinical criteria for the use of symptomatic slow-acting drug for osteoarthritis (SYSADOA). A Delphi method consensus initiative among experts in Italy.

  2019cites this paper
• Effect of glucosamine sulfate on intraocular pressure in patients with knee osteoarthritis: A prospective randomized controlled trial.

  2019cites this paper
• An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

  2019cites this paper
• Osteoarthritis treatment: Is it finally time to consider glucosamine seriously?

  2019cites this paper
• Dietary Botanicals and Supplements

  2019cites this paper
• International endorsement of the ESCEO algorithm for management of knee osteoarthritis in clinical practice.

  2017cites this paper